Eikon Therapeutics (NASDAQ: EIKN) director discloses 85,937-share stock option grant
Rhea-AI Filing Summary
Eikon Therapeutics director Francisco Ma. Fatima reported an initial holding of a stock option covering 85,937 shares of Common Stock. The option has an exercise price of $8.9600 per share and expires on June 4, 2036. According to the vesting terms, 1/48th of the underlying shares vest each month over 48 months, conditioned on continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Francisco Ma. Fatima
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 85,937 shares (Direct)
Footnotes (1)
- F1. 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date.
Key Figures
Underlying option shares: 85,937 shares
Exercise price: $8.9600 per share
Option expiration: June 4, 2036
+2 more
5 metrics
Underlying option shares
85,937 shares
Common Stock underlying reported stock option
Exercise price
$8.9600 per share
Stock option exercise price
Option expiration
June 4, 2036
Expiration date of stock option
Post-report option position
85,937 units
Total options following reported holding entry
Vesting rate
1/48 per month
Monthly vesting over 48 months with continued service
Key Terms
Stock Option (Right to Buy), underlying security, exercise price, vesting, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
underlying security financial
"underlying_security_title: Common Stock"
exercise price financial
"conversion_or_exercise_price: 8.9600"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"1/48th of the shares underlying the option will vest on each monthly anniversary"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Form 3 regulatory
"INSIDER FILING DATA (Form 3)"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does the EIKN Form 3 filing report for Francisco Ma. Fatima?
The Form 3 shows director Francisco Ma. Fatima holds a stock option on 85,937 Eikon Therapeutics shares. This filing discloses his initial derivative position as an insider, rather than a new market transaction or purchase.
What is the exercise price of Francisco Ma. Fatima’s EIKN stock option?
The option has an exercise price of $8.9600 per share. This is the price at which the director can purchase Eikon Therapeutics Common Stock if and when the option vests and he chooses to exercise it.
When does the reported Eikon Therapeutics stock option expire?
The stock option reported for Francisco Ma. Fatima expires on June 4, 2036. After that expiration date, any unexercised portion of the option will no longer be exercisable under the disclosed terms.
How does the vesting schedule work for the EIKN director’s stock option?
The vesting schedule grants 1/48th of the underlying shares on each monthly anniversary of the vesting start date for 48 months. Vesting is contingent on the director’s continued service through each monthly vesting date.